Immune response to three doses of mRNA SARS-CoV-2 vaccines in CD19-targeted chimeric antigen receptor T cell immunotherapy recipients

Cancer Cell. 2022 Mar 14;40(3):236-237. doi: 10.1016/j.ccell.2022.01.010. Epub 2022 Jan 25.

Authors

Pierre Sesques¹, Emmanuel Bachy¹, Emmanuelle Ferrant¹, Violaine Safar¹, Morgane Gossez¹, Florence Morfin-Sherpa¹, Fabienne Venet¹, Florence Ader²

Affiliations

¹ Lyon University Hospital, Lyon, France.
² Lyon University Hospital, Lyon, France. Electronic address: florence.ader@chu-lyon.fr.

No abstract available

Publication types

Letter
Observational Study

MeSH terms

Aged
Antigens, CD19 / immunology*
COVID-19 / immunology*
COVID-19 / prevention & control
COVID-19 / virology
COVID-19 Vaccines / administration & dosage
COVID-19 Vaccines / immunology*
Female
Hematologic Neoplasms / immunology
Hematologic Neoplasms / therapy
Humans
Immunity / drug effects
Immunity / immunology
Immunity, Cellular / drug effects
Immunity, Cellular / immunology
Immunity, Humoral / drug effects
Immunity, Humoral / immunology
Immunotherapy, Adoptive / methods*
Male
Middle Aged
Prospective Studies
Receptors, Chimeric Antigen / immunology*
SARS-CoV-2 / drug effects
SARS-CoV-2 / immunology*
SARS-CoV-2 / physiology
T-Lymphocytes / immunology*
Vaccination / methods

Substances

Antigens, CD19
COVID-19 Vaccines
Receptors, Chimeric Antigen